Aporkalypse Next: Pulmatrix Moves Broad-Spectrum Inhaled Anti-Infective Into Phase II
This article was originally published in The Pink Sheet Daily
Executive Summary
Privately held biotech believes its approach will improve on flu vaccines by enhancing the body’s own defenses to fight off a variety of pathogens.